The use of fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA), such as the once-daily formulations insulin degludec/liraglutide (IDegLira) or insulin glargine 100 U/ml plus lixisenatide (IGlarLixi), has been shown to be efficacious with respect to improving glycaemic management while also being associated with other benefits such as less weight gain, a lower risk of hypoglycaemia and a lower insulin dose than with basal bolus insulin therapy. This evidence concerns the gene GLP1R and Hypoglycemia.